Capmatinib belongs to the first generation of targeted therapy drugs

Capmatinib (Capmatinib) is a small molecule targeted therapy drug for MET gene abnormalities. It is a first-generation MET inhibitor. METGene abnormalities, especially METexon14 skipping (METex14 skipping mutation), plays an important role in promoting tumor occurrence and progression in various cancers, especially non-small cell lung cancer (NSCLC). Capmatinib effectively and selectively inhibits the activity of MET receptor tyrosine kinase, thereby blocking the proliferation and migration of tumor cells, providing a new treatment option for patients with specific genetic backgrounds.

In clinical application, capmatinib is mainly used to treat patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping. Capmatinib demonstrated good treatment response rates regardless of whether patients had received prior therapy. Especially among patients who have not received systemic treatment, the objective response rate of capmatinib is more outstanding, and some patients can obtain durable remission. This precise targeting feature makes capmatinib a new first-line treatment option for patients with MET abnormalities.

Although capmatinib is a first-generation MET inhibitor, it exhibits better drug selectivity and less off-target effects. Compared with traditional chemotherapy, the side effects of capmatinib are relatively controllable. Common adverse reactions include peripheral edema, nausea, vomiting, and abnormal liver function. Most of them are mild to moderate. Patients can continue treatment after reasonable management. Therefore, capmatinib not only improves patients' quality of life, but also creates conditions for prolonging progression-free survival.

Overall, capmatinib, as the first generation of MET targeted drugs, marks a major advancement in the field of precision treatment of lung cancer. As more research proceeds, inhibition strategies targeting the MET pathway are being continuously optimized, and a new generation of drugs with more efficiency and lower drug resistance is expected to emerge in the future. However, at this stage, capmatinib is still an important treatment option for patients with METExon14 skip-transition non-small cell lung cancer, providing this special population with tangible survival benefits.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib